skip to content
Primary navigation


DrugAdmelog® (insulin lispro) [Sanofi-Aventis U.S. LLC]

July 2018

Therapeutic area - Insulin

Approval criteria

  • Patient is allergic to Humalog OR
  • Patient has an inadequate response to Humalog but has had a demonstrated adequate response to the Admelog OR
  • Patient is unable to change to Humalog due to a cognitive or developmental disability OR
  • Changing to Humalog would create undue hardship for the patient

Quantity limits

  • 90 mL per 34 days


Admelog is approved by the FDA under the New Drug Application (NDA) pathway and is not considered an interchangeable biosimilar to Humalog. Admelog is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top